Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses

Subsets of multiple myeloma (MM) and monoclonal gammopathies of undetermined significance (MGUS) present with a monoclonal immunoglobulin specific for hepatitis C virus (HCV), thus are presumably HCV-driven, and antiviral treatment can lead to the disappearance of antigen stimulation and improved co...

Descripción completa

Detalles Bibliográficos
Autores: Rodríguez-García, Alba, Mennesson, Nicolas, Hernandez-Ibarburu, Gema, Morales, María Luz, Garderet, Laurent, Bouchereau, Lorine, Allain-Maillet, Sophie, Piver, Eric, Marbán, Irene, Rubio, David, Bigot-Corbel, Edith, Martinez-Lopez, Joaquin, Linares, María, Hermouet, Sylvie
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/23115
Acceso en línea:https://hdl.handle.net/20.500.12105/23115
Access Level:acceso abierto
Palabra clave:Multiple Myeloma
Hepatitis B
Hepatitis C
Monoclonal Gammopathy of Undetermined Significance
Humans
Hepatitis B virus
Antiviral Agents
id ES_d88f9c1a113e01e280e7539fbb68cfaf
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/23115
network_acronym_str ES
network_name_str España
repository_id_str
spelling Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C virusesRodríguez-García, AlbaMennesson, NicolasHernandez-Ibarburu, GemaMorales, María LuzGarderet, LaurentBouchereau, LorineAllain-Maillet, SophiePiver, EricMarbán, IreneRubio, DavidBigot-Corbel, EdithMartinez-Lopez, JoaquinLinares, MaríaHermouet, SylvieMultiple MyelomaHepatitis BHepatitis CMonoclonal Gammopathy of Undetermined SignificanceHumansHepatitis B virusAntiviral AgentsSubsets of multiple myeloma (MM) and monoclonal gammopathies of undetermined significance (MGUS) present with a monoclonal immunoglobulin specific for hepatitis C virus (HCV), thus are presumably HCV-driven, and antiviral treatment can lead to the disappearance of antigen stimulation and improved control of clonal plasma cells. Here we studied the role of hepatitis B virus (HBV) in the pathogenesis of MGUS and MM in 45 HBV-infected patients with monoclonal gammopathy. We analyzed the specificity of recognition of the monoclonal immunoglobulin of these patients and validated the efficacy of antiviral treatment (AVT). For 18 of 45 (40%) HBV-infected patients, the target of the monoclonal immunoglobulin was identified: the most frequent target was HBV (n=11), followed by other infectious pathogens (n=6) and glucosylsphingosine (n=1). Two patients whose monoclonal immunoglobulin targeted HBV (HBx and HBcAg), implying that their gammopathy was HBV-driven, received AVT and the gammopathy did not progress. AVT efficacy was then investigated in a large cohort of HBV-infected MM patients (n=1367) who received or did not receive anti-HBV treatments and compared to a cohort of HCV-infected MM patients (n=1220). AVT significantly improved patient probability of overall survival (P=0.016 for the HBV-positive cohort, P=0.005 for the HCV-positive cohort). Altogether, MGUS and MM disease can be HBV- or HCV-driven in infected patients, and the study demonstrates the importance of AVT in such patients.Fondazione Ferrata StortiLigue Nationale Contre le Cancer (Francia)Spanish Society of Hematology20242024-09-1620242024-01-0120242024-01-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articlehttps://hdl.handle.net/20.500.12105/23115reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/231152026-06-12T12:43:37Z
dc.title.none.fl_str_mv Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses
title Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses
spellingShingle Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses
Rodríguez-García, Alba
Multiple Myeloma
Hepatitis B
Hepatitis C
Monoclonal Gammopathy of Undetermined Significance
Humans
Hepatitis B virus
Antiviral Agents
title_short Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses
title_full Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses
title_fullStr Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses
title_full_unstemmed Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses
title_sort Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses
dc.creator.none.fl_str_mv Rodríguez-García, Alba
Mennesson, Nicolas
Hernandez-Ibarburu, Gema
Morales, María Luz
Garderet, Laurent
Bouchereau, Lorine
Allain-Maillet, Sophie
Piver, Eric
Marbán, Irene
Rubio, David
Bigot-Corbel, Edith
Martinez-Lopez, Joaquin
Linares, María
Hermouet, Sylvie
author Rodríguez-García, Alba
author_facet Rodríguez-García, Alba
Mennesson, Nicolas
Hernandez-Ibarburu, Gema
Morales, María Luz
Garderet, Laurent
Bouchereau, Lorine
Allain-Maillet, Sophie
Piver, Eric
Marbán, Irene
Rubio, David
Bigot-Corbel, Edith
Martinez-Lopez, Joaquin
Linares, María
Hermouet, Sylvie
author_role author
author2 Mennesson, Nicolas
Hernandez-Ibarburu, Gema
Morales, María Luz
Garderet, Laurent
Bouchereau, Lorine
Allain-Maillet, Sophie
Piver, Eric
Marbán, Irene
Rubio, David
Bigot-Corbel, Edith
Martinez-Lopez, Joaquin
Linares, María
Hermouet, Sylvie
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Ligue Nationale Contre le Cancer (Francia)
Spanish Society of Hematology
dc.subject.none.fl_str_mv Multiple Myeloma
Hepatitis B
Hepatitis C
Monoclonal Gammopathy of Undetermined Significance
Humans
Hepatitis B virus
Antiviral Agents
topic Multiple Myeloma
Hepatitis B
Hepatitis C
Monoclonal Gammopathy of Undetermined Significance
Humans
Hepatitis B virus
Antiviral Agents
description Subsets of multiple myeloma (MM) and monoclonal gammopathies of undetermined significance (MGUS) present with a monoclonal immunoglobulin specific for hepatitis C virus (HCV), thus are presumably HCV-driven, and antiviral treatment can lead to the disappearance of antigen stimulation and improved control of clonal plasma cells. Here we studied the role of hepatitis B virus (HBV) in the pathogenesis of MGUS and MM in 45 HBV-infected patients with monoclonal gammopathy. We analyzed the specificity of recognition of the monoclonal immunoglobulin of these patients and validated the efficacy of antiviral treatment (AVT). For 18 of 45 (40%) HBV-infected patients, the target of the monoclonal immunoglobulin was identified: the most frequent target was HBV (n=11), followed by other infectious pathogens (n=6) and glucosylsphingosine (n=1). Two patients whose monoclonal immunoglobulin targeted HBV (HBx and HBcAg), implying that their gammopathy was HBV-driven, received AVT and the gammopathy did not progress. AVT efficacy was then investigated in a large cohort of HBV-infected MM patients (n=1367) who received or did not receive anti-HBV treatments and compared to a cohort of HCV-infected MM patients (n=1220). AVT significantly improved patient probability of overall survival (P=0.016 for the HBV-positive cohort, P=0.005 for the HCV-positive cohort). Altogether, MGUS and MM disease can be HBV- or HCV-driven in infected patients, and the study demonstrates the importance of AVT in such patients.
publishDate 2024
dc.date.none.fl_str_mv 2024
2024-09-16
2024
2024-01-01
2024
2024-01-01
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.12105/23115
url https://hdl.handle.net/20.500.12105/23115
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Fondazione Ferrata Storti
publisher.none.fl_str_mv Fondazione Ferrata Storti
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421183505530880
score 15,811543

Similares en LA Referencia